Inhibition of apolipoprotein A-I gene expression by obesity-associated endocannabinoids

Obesity

Volumn 20, Issue 4, 2012, Pages 721-729

  Haas, Michael J ^a   Mazza, Angela D ^b   Wong, Norman C W ^c   Mooradian, Arshag D ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; APOLIPOPROTEIN A1; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CELL NUCLEUS RECEPTOR; MESSENGER RNA;

APOLIPOPROTEIN A I GENE; ARTICLE; BINDING SITE; CELL STRAIN CACO 2; CELL STRAIN HEPG2; CONTROLLED STUDY; DNA PROTEIN COMPLEX; GENE; GENE DELETION; GENE EXPRESSION REGULATION; GENE REPRESSION; OBESITY; PROMOTER REGION; PROTEIN BINDING; PROTEIN SECRETION;

APOLIPOPROTEIN A-I; ARACHIDONIC ACIDS; BLOTTING, NORTHERN; BLOTTING, WESTERN; ENDOCANNABINOIDS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLYCERIDES; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIPOPROTEINS, HDL; LIVER; POLYUNSATURATED ALKAMIDES; RNA, MESSENGER;

EID: 84859219081     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2011.323     Document Type: Article

References (41)

1. Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1999;143:315-317. (Pubitemid 29204987)
2. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002;136:550-557. (Pubitemid 34717699)
3. D'Amico M, Cannizzaro C, Preziosi P, Martire M. Inhibition by anandamide and synthetic cannabimimetics of the release of [3H]D-aspartate and [3H] GABA from synaptosomes isolated from the rat hippocampus. Neurochem Res 2004;29:1553-1561. (Pubitemid 38860238)
4. Katona I, Rancz EA, Acsady L et al. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci 2001;21:9506-9518. (Pubitemid 33096895)
5. Blüher M, Engeli S, Klöting N et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006;55:3053-3060. (Pubitemid 44923642)
6. Matias I, Gonthier MP, Orlando P et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and ?-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006;91:3171-3180. (Pubitemid 44271774)
7. Côté M, Matias I, Lemieux I et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007;31:692-699. (Pubitemid 46482358)
8. Berdyshev EV, Boichot E, Germain N et al. Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur J Pharmacol 1997;330: 231-240. (Pubitemid 27296727)
9. Cabral GA, Dove Pettit DA. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol 1998;83:116-123. (Pubitemid 28280957)
10. Nogueiras R, Rohner-Jeanrenaud F, Woods SC, Tschöp MH. The endocannabinoid system and the control of glucose homeostasis. J Neuroendocrinol 2008;20 Suppl 1:147-151. (Pubitemid 351552686)
11. Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-2134. (Pubitemid 41653104)
12. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 2006;368:1660-1672. (Pubitemid 46048528)
13. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-775. (Pubitemid 43244304)
14. Scheen AJ. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. J Neuroendocrinol 2008;20 Suppl 1:139-146. (Pubitemid 351559287)
15. Mooradian AD, Haas MJ, Wehmeier KR, Wong NC. Obesity-related changes in high-density lipoprotein metabolism. Obesity (Silver Spring) 2008;16:1152-1160. (Pubitemid 351770500)
16. Calpe-Berdiel L, Rotllan N, Palomer X et al. Direct evidence in vivo of impaired macrophage-specific reverse cholesterol transport in ATP-binding cassette transporter A1-deficient mice. Biochim Biophys Acta 2005;1738:6-9. (Pubitemid 43122125)
17. Mukherjee R, Locke KT, Miao B et al. Novel peroxisome proliferator-activated receptor agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist. J Pharmacol Exp Ther 2008;327:716-726.
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
19. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
20. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350-4354. (Pubitemid 9256559)
21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159. (Pubitemid 17064313)
22. Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983;132:6-13.
23. Haas MJ, Horani M, Mreyoud A et al. Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF̈?and IL-1?. Biochim Biophys Acta 2003;1623:120-128. (Pubitemid 37315668)
24. Taylor AH, Wishart P, Lawless DE, Raymond J, Wong NC. Identification of functional positive and negative thyroid hormone-responsive elements in the rat apolipoprotein AI promoter. Biochemistry 1996;35:8281-8288. (Pubitemid 26234931)
25. Gorman CM, Moffat LF, Howard BH. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 1982;2:1044-1051. (Pubitemid 13227227)
26. Herbomel P, Bourachot B, Yaniv M. Two distinct enhancers with different cell specificities coexist in the regulatory region of polyoma. Cell 1984;39:653-662. (Pubitemid 15198603)
27. Cox GS, Gutkin DW, Haas MJ, Cosgrove DE. Isolation of an Alu repetitive DNA binding protein and effect of CpG methylation on binding to its recognition sequence. Biochim Biophys Acta 1998;1396:67-87. (Pubitemid 28131447)
28. Widom RL, Ladias JA, Kouidou S, Karathanasis SK. Synergistic interactions between transcription factors control expression of the apolipoprotein AI gene in liver cells. Mol Cell Biol 1991;11:677-687. (Pubitemid 21895415)
29. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-65. (Pubitemid 23305569)
30. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564.
31. Devane WA, Hanus L, Breuer A et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258: 1946-1949. (Pubitemid 23026736)
32. Sugiura T, Kondo S, Sukagawa A et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995;215:89-97.
33. O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 2007; 152:576-582. (Pubitemid 350034977)
34. Zygmunt PM, Petersson J, Andersson DA et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999;400:452-457. (Pubitemid 29361798)
35. Osei-Hyiaman D, DePetrillo M, Pacher P et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005;115:1298-1305. (Pubitemid 40629049)
36. Biswas KK, Sarker KP, Abeyama K et al. Membrane cholesterol but not putative receptors mediates anandamide-induced hepatocyte apoptosis. Hepatology 2003;38:1167-1177. (Pubitemid 37314825)
37. Sarker KP, Maruyama I. Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts. Cell Mol Life Sci 2003;60:1200-1208. (Pubitemid 36791921)
38. Giuliano M, Calvaruso G, Pellerito O et al. Anandamide-induced apoptosis in Chang liver cells involves ceramide and JNK/AP-1 pathway. Int J Mol Med 2006;17:811-819.
39. Beier K, Völkl A, Fahimi HD. TNF-downregulates the peroxisome proliferator activated receptor-and the mRNAs encoding peroxisomal proteins in rat liver. FEBS Lett 1997;412:385-387. (Pubitemid 27321288)
40. Beers A, Haas MJ, Wong NC, Mooradian AD. Inhibition of apolipoprotein AI gene expression by tumor necrosis factor ?: roles for MEK/ERK and JNK signaling. Biochemistry 2006;45:2408-2413. (Pubitemid 43271341)
41. Zheng XL, Matsubara S, Diao C, Hollenberg MD, Wong NC. Activation of apolipoprotein AI gene expression by protein kinase A and kinase C through transcription factor, Sp1. J Biol Chem 2000;275:31747-31754.